Phase II Study of the Safety and Antitumour Activity of Apatinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck

2018 ◽  
Author(s):  
Guopei Zhu ◽  
Lin Zhang ◽  
Shengjin Dou ◽  
Rongrong Li ◽  
Li Xie ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Antitumour Activity ◽  
Adenoid Cystic

A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

Oral Oncology ◽  
2007 ◽  
Vol 43 (1) ◽  
pp. 33-36 ◽  
Author(s):  
M. Raphael Pfeffer ◽  
Yoav Talmi ◽  
Raphael Catane ◽  
Zvi Symon ◽  
Ady Yosepovitch ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Salivary Glands ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

2008 ◽  
Vol 44 (17) ◽  
pp. 2542-2545 ◽  
Author(s):  
C.M.L. van Herpen ◽  
L.D. Locati ◽  
J. Buter ◽  
J. Thomas ◽  
J. Bogaerts ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC)

2008 ◽  
Vol 6 (12) ◽  
pp. 65 ◽  
Author(s):  
S.J. Hotte ◽  
E.X. Chen ◽  
H.W. Hirte ◽  
P. Moretto ◽  
S. Turner ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

142 Phase II study of imatinib mesylate in salivary gland adenoid cystic carcinoma

2003 ◽  
Vol 1 (5) ◽  
pp. S46-S47 ◽  
Author(s):  
E. Winquist ◽  
E. Lamont ◽  
S. Hotte ◽  
M. MacKenzie ◽  
S. Brown ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Adenoid Cystic Carcinoma ◽  
Imatinib Mesylate ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 6093-6093 ◽  
Author(s):  
Alan Loh Ho ◽  
Eric Jeffrey Sherman ◽  
Matthew G. Fury ◽  
Shrujal S. Baxi ◽  
Sofia Haque ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

scholarly journals A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

2017 ◽  
Vol 23 (15) ◽  
pp. 4138-4145 ◽  
Author(s):  
Patrick M. Dillon ◽  
Gina R. Petroni ◽  
Bethany J. Horton ◽  
Christopher A. Moskaluk ◽  
Paula M. Fracasso ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Adenoid Cystic

Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: A phase II study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6086-6086 ◽  
Author(s):  
J. M. Guigay ◽  
F. Bidault ◽  
S. Temam ◽  
F. Janot ◽  
E. Raymond ◽  
...  
Keyword(s):  
Tumor Progression ◽  
Adenoid Cystic Carcinoma ◽  
Salivary Glands ◽  
Phase Ii ◽  
Pulmonary Metastasis ◽  
Phase Ii Study ◽  
Previous Treatment ◽  
Duration Of Treatment ◽  
Antitumor Effects ◽  
Adenoid Cystic

6086 Background: Adenoid cystic carcinoma (ACC) of the salivary glands is a rare orphan disease of the head and neck usually resistant to conventional chemotherapy, that was found to express KIT in 87% (39/45) of cases in our institutions. Methods: This study explored the antitumor effects of imatinib given at 800 mg daily in a phase II study for patients (pts) with recurrent or metastatic ACC failing locoregional treatments, presenting CT-scan documented progressive disease and highly (50–100% of tumor cells) expressing KIT. Primary endpoint of this study was time to tumor progression, secondary endpoints were tumor response and safety. Results. Since 2004, 17 pts (M/F: 5/12, median age 48, range 33–71) were included. Target lesions were pulmonary metastasis (13 pts), renal metastasis (1 pt), locoregional (2 pts) and pulmonary + locoregional (1 pt) recurrences. Previous treatment with chemotherapy was reported in 5 pts. Median duration of treatment was 6 months (range, 1–14 months). Toxicity was mild to moderate except for 2 pts who had grade 3–4 anemia/neutropenia and asthenia requiring dose reduction and early study withdrawal, respectively. Among 15 evaluable pts with tumor progression at study entry, 5 pts were stable after 6+, 8, 9, 12+ and 18+ months of follow-up and 2 pts displayed partial responses of 42% and 35% (RECIST). These objective responses were associated with early symptomatic improvement (dyspnea/pain) and occurred in platinum- resistant pulmonary metastasis and a radiation-pre-treated locoregional recurrence, lasting 14 months and 9+ months, respectively. Final accrual and TTP determinations are ongoing. Conclusion. Although sporadic, objective responses can be observed in patients with progressive ACC treated with imatinib as well as long-lasting tumor stabilisations. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document